Angela Lombardo

发表

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Title Phase I safety and immunogenicity evaluation of ADVAX , aMultigenic , DNA-based Clade C / B ' HIV-1 candidate vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010 .

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.

S. Kochhar, J. Excler, P. Fast, 2009, AIDS research and human retroviruses.

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.

N. Frahm, E. Karita, M. McElrath, 2016, Annals of internal medicine.

Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults

B. Gazzard, G. Alter, M. Boffito, 2013, Clinical and Vaccine Immunology.

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Allan C. deCamp, Jordan R. Willis, D. Montefiori, 2022, Science.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

Yang Song, Soe Than, Martin Ho, 2010, PloS one.

Use of Transient Transfection for cGMP Manufacturing of eOD-GT8 60mer, a Self-Assembling Nanoparticle Germline-Targeting HIV-1 Vaccine Candidate

W. Schief, S. Menis, V. Tsvetnitsky, 2022, bioRxiv.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults

G. Omosa-Manyonyi, E. Chomba, J. Mpendo, 2015, PloS one.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

J. Treanor, M. Havenga, D. Barouch, 2018, PloS one.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

B. Gazzard, E. Karita, O. Anzala, 2016, The Journal of infectious diseases.

A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses

Allan C. deCamp, R. Koup, Greg Finak, 2023, Science Translational Medicine.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.

S. Kochhar, J. Excler, P. Fast, 2009, AIDS research and human retroviruses.

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.

Allan C. deCamp, Jordan R. Willis, R. Koup, 2023, medRxiv : the preprint server for health sciences.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

G. Zaharatos, P. Fast, J. Cox, 2010, PloS one.